19
Tuesday
January 2021
2:57 PM IST
News Headlines
England beats Sri Lanka by 7 wickets in 1st test        Fourth Test: Rain forces early stumps with India at 4-0 while chasing 328 to win        Three UK partners with TCS to accelerate 5G network rollout        3 Adani Group-owned domestic airports accredited in ACI health accreditation programme        N. Korea''s parliament rubber stamps new development plans        Kremlin critic Navalny detained after landing in Moscow        'Rooting hard for you': Will departure notes end with Trump?        Tandav controversy: FIR against director, Amazon India head of content        Smiles, sanitizers welcome students as schools reopen in Delhi        COVID-19: India records lowest fatalities in eight months        Proposed tractor rally on Jan 26: It's law & order matter, says SC on plea for injunction against it        PM flags off 8 trains to boost connectivity to Statue of Unity        Fire in luggage van of running train doused in time in Kerala        Kerala logs 5,005 new COVID-19 cases, 4,408 recoveries        Farmer unions say they will go ahead with tractor march in Delhi on Republic Day        Kremlin critic Navalny departs Berlin on Moscow-bound flight        Cargo ship sinks in the Black Sea; 3 dead, 6 rescued        4th Test: Australia 21/0 at stumps, lead India by 54 runs after Sundar, Thakur fightback        NorthEast end winless streak to bag crucial points against Jamshedpur        India take tea break at 62/2, replying to Australia's 369        
Home   | Main News   | Kerala  | National   | International  | Business   | Sports   | Entertainment   | Columns   | Offbeat   | Health   | About Deepika 
Main News
Pfizer, BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, say it's 95% effective
 
New York, Nov 18 (PTI) Global drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial, including in people aged over 65 years, paving the way for the companies to apply for emergency authorisation from US regulators within days

American pharmaceutical giant Pfizer and its German partner BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy end points

Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021

The major announcement comes just two days after leading biotechnology company Moderna said on Monday its virus vaccine had an efficacy rate of 94.5 per cent

Earlier this month, Pfizer and Biontech had said their COVID-19 vaccine candidate was found to be more than 90 per cent effective in preventing COVID-19 in participants

Analysis of the data indicates a vaccine efficacy rate of 95 per cent in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from seven days after the second dose

The companies said the first primary objective analysis is based on 170 cases of COVID-19, of which 162 cases of coronavirus were observed in the placebo group while 8 cases in the BNT162b2 group

Vaccine efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94 per cent, they said

There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world," said Dr Albert Bourla, Pfizer Chairman and CEO

"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," Bourla said

The announcements about the vaccines and their potential availability for use among the general population in the coming weeks and months has offered hope to millions around the world in a year that has seen the COVID-19 pandemic devastate lives and economies and still showing no signs of abating

So far, the coronavirus pandemic has infected more than 55 million people around the world and killed more than 1.3 million people even as governments implemented strict lockdowns and restrictions to slow the spread of the virus that originated in the Chinese city of Wuhan

A second wave of infections is threatening to derail economies and impact lives again as countries had gradually begun to ease restrictions and open up

Pfizer said till date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine

A randomised subset of at least 8,000 participants 18 years and older in the phase 2/3 study found that the vaccine was well tolerated and any side effects resolved shortly after vaccination

The sides-effects noticed after the first or second dose was fatigue, and headache. Further, older adults tended to report fewer and milder side-effects following vaccination

With the safety milestone required by the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) being achieved, Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA based on the totality of safety and efficacy data collected to date, as well as manufacturing data relating to the quality and consistency of the vaccine

BioNTech MD, CEO and Co-founder Ugur Sahin said the final efficacy analysis indicates that a high rate of protection against COVID-19 can be achieved very fast after the first 30 ?g dose

"Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages. We believe we have achieved this with our vaccine candidate BNT162b2 in all age groups studied so far and look forward to sharing further details with the regulatory authorities," Sahin said

The Phase 3 clinical trial of BNT162b2 began in July and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13

Approximately 42 per cent of global participants and 30 per cent of US participants have racially and ethnically diverse backgrounds, and 41 per cent of global and 45 per cent of US participants are 56-85 years of age

Four of Pfizer's facilities are part of the manufacturing and supply chain; St. Louis, Andover, and Kalamazoo in the U.S and Puurs in Belgium. BioNTech's German sites will also be leveraged for global supply

Pfizer said it is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world. The companies have developed specially designed, temperature-controlled thermal shippers utilising dry ice to maintain temperature conditions of -70?C?10?C.


Proposed tractor rally on Jan 26: It's law & order matter, says SC on plea for injunction against it
Farmer unions say they will go ahead with tractor march in Delhi on Republic Day
PM launches India's vaccination drive against COVID-19
LDF govt presents welfare oriented budget; oppn questions exercise before election
CM Oppn blasts Kerala CM on gold smuggling case in assembly
US House impeaches President Donald Trump for ''incitement of insurrection'' at Capitol
SC rejects Centre''s vehement plea not to stay farm laws, says it''s not powerless
SC raps Centre over prolonged impasse with protesting farmers, indicates it may stay implementation of farm laws
Bird flu confirmed in 7 states; test results of Delhi, Maharashtra samples awaited
COVID-19 vaccination to start in India on Jan 16; 3 cr healthcare, frontline workers to get shots first
Govt-farmers meeting ends; Next round of talks likely on Jan 15
SC seeks response of Centre on PIL against three farm laws
Trump supporters enter US Capitol in massive breach of security
COVID-19: India records lowest daily cases in over six months
India records 16,504 new COVID-19 cases, 214 fresh fatalities
Every farmer-labourer part of movement a 'satyagrahi', they will take back their rights: Rahul
India records less than 20,000 fresh COVID-19 cases; no. of recoveries goes past 99 lakh
Will have to take firm steps if talks with govt on January 4 fail: Farmer unions
PM cautions against rumours on Corona vaccine, 'Dawai Bhi aur kadai bhi'
Farmers protesting at Delhi borders firm in their demands as Centre, farm unions set to resume talks
KERALA NEWS
Fire in luggage van of running train doused in time in Kerala
 Thiruvananthapuram: A fire broke out in a luggage van of a running train in Kerala on Sunday and was  
Kerala logs 5,005 new COVID-19 cases, 4,408 recoveries
5,960 new COVID-19 cases, 27 deaths in Kerala
Kerala transport corporation MD alleges Rs 100-crore scam
INTERNATIONAL NEWS
N. Korea''s parliament rubber stamps new development plans
 Seoul, Jan 18 (AP) North Korea's rubber-stamp parliament has passed decisions made by a major ruling
Kremlin critic Navalny detained after landing in Moscow
'Rooting hard for you': Will departure notes end with Trump?
Kremlin critic Navalny departs Berlin on Moscow-bound flight
NATIONAL NEWS
Tandav controversy: FIR against director, Amazon India head of content
 Lucknow Jan 18 (PTI) An FIR has been lodged here against the makers of web series 'Tandav' and Amazo
Smiles, sanitizers welcome students as schools reopen in Delhi
COVID-19: India records lowest fatalities in eight months
PM flags off 8 trains to boost connectivity to Statue of Unity
Untitled Page
Rashtra Deepika LTD
Copyright @ 2020 , Rashtra Deepika Ltd.